Screening for cervical cancer has dramatically helped reduce its incidence and mortality—age-adjusted death rates have been falling on average 0.7% each year over 2009–2022.1
You can count on Quest for a more complete picture to help you and your patients make more informed decisions.
Quest’s age-based Smart Codes use a patient’s age and risk factors to determine which combination of HPV and select STI screening should be performed, along with an image-guided Pap. Smart Codes are consistent with ACOG recommendationsa and are available in addition to our standard menu of tests.
With our robust cervical cancer testing menu, you can rely on Pap testing from Quest Diagnostics to help you make a more informed diagnosis and treatment plan for your patients.
While we offer a choice of Pap collection systems, Quest Diagnostics recommends the ThinPrep® Pap test, due to its proven clinical performance
TEST CODE | TEST NAME |
---|---|
91384 |
Image-Guided Pap with Age-Based Screening Protocols |
91385 |
Image-Guided Pap with Age-Based Screening with CT/NG |
91386 |
Image-Guided Pap with Age-Based Screening with CT/NG, Trichomonas |
The Aptima® HPV mRNA assay identifies the presence and activity of high-risk HPV infections, allowing you to identify and focus on those women who most need your care.
Leading health organizations recommend co-testing every 5 years for women ages 30 to 65 as the preferred method for cervical cancer screening, and a recent Quest Diagnostics Health Trends™ retrospective, longitudinal study confirms that co-testing with Pap and HPV together identifies more cases of cancer and precancer.2
22.5% of cancers would not have been identified with HPV alone2
Data <12 months of cancer diagnosis
11% of precancers would not have been identified with Pap alone2
Data <12 months of precancer diagnosis
Data on biopsy-confirmed cancer outcomes over the entire study period (9 years)
Co-tests prior to biopsy-confirmed cancer = 1,615
Adenocarcinoma is on the rise8
Co-tests prior to biopsy-confirmed adenocarcinoma = 479
Our co-testing solutions for cervical cancer are built on a strong combination of carefully evaluated Pap and high performing mRNA testing for high risk HPV. Ordering cervical cancer screening is efficient using one-click Smart Codes. For more information or a complete list of our tests, visit our test directory.
a ACOG recommendations do not specify a particular type of Pap test. Both imaged and nonimaged Pap tests are acceptable under the recommendations. Information on nonimaged Pap tests can be found at QuestDiagnostics.com/TestDirectory.
b Defined as 3 consecutive negative Paps or 2 consecutive negative co-tests within the past 10 years, with the most recent test occurring within the past 5 years.
Test codes may vary by location. Please contact your local laboratory for more information.
References: